Global Partners L.P. (GLP)
NYSE NYSE Primary 
Older GLP-1 drug from Novo Nordisk may slow Alzheimer's disease progression by protecting the brain, study says
An older, once-daily drug for diabetes and obesity from Novo Nordisk called liraglutide may slow the progression of Alzheimer's disease by protecting patients' brains, according to data from a mid-stage trial. Novo Nordisk sells liraglutide under the brand names Saxenda and Victoza, which are seeing sales decline as demand for the company's weekly diabetes injection Ozempic and weight loss shot Wegovy skyrockets.
Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment
Results from phase 3 RESILIENT study, using taldefgrobep alfa for the treatment of patients with spinal muscular atrophy, expected in the 2nd half of 2024. The global spinal muscular atrophy treatment market is projected to reach $8.4 billion by 2032. Preclinical model testing showed that myostatin inhibitor taldefgrobep alfa + GLP-1 inhibitor was able to show greater reductions in body weight and fat loss, compared to that of GLP-1 alone.
Hims & Hers Health: Expecting A Healthy Report
Hims & Hers Health has fallen below $20 after initial excitement over a compounded GLP-1 drug solution wanes. The health and wellness platform offers a compounded semaglutide drug at lower prices due to shortage of name-brand drugs. A short report from Hunterbrook Media questioned the business practices, but the investment story isn't based on the GLP-1 drug compound.
Hims & Hers: The Thesis Goes Far Beyond GLP-1
Hims & Hers is dedicated to telehealth and provides healthcare services remotely. It has an asset-light business model that has had extraordinary growth. The company began its growth by attacking markets sometimes overlooked by traditional medicine, such as dermatology or mental health. According to my valuation model, the stock could triple if it grows 35% annually in the coming years and reaches EBITDA margins of 25%. In my opinion, it's realistic.
Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study
DehydraTECH appears to work with a second GLP-1 drug - liraglutide DehydraTECH appears to be working with semaglutide both with and without SNAC technology DehydraTECH-CBD is showing strong apparent performance relative to GLP-1 Dosing in the final four study arms has now begun KELOWNA, BC / ACCESSWIRE / July 17, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that interim results from the first four weeks of dosing in its ongoing diabetes animal study WEIGHT-A24-1 (the "Study") have been received and have already produced several noteworthy findings. Unlimited food and water has been provided to the animals for the entire duration of the Study.
Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics
GLP-1 medicines for obesity are all the rage these days. Viking Therapeutics' candidate has the edge in the speed of weight loss.
Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study
All three dosing arms have been completed. KELOWNA, BC / ACCESSWIRE / July 9, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that human pilot study #2, GLP-1-H24-2, (the "Study") has now completed all dosing.
Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug
Global pharmaceutical company Eli Lilly & Co. NYSE: LLY has been in a GLP-1 arms race with its FDA-approved therapies Mounjaro and Zepbound. It's been going heads-up against GLP-1 leader Novo Nordisk A/S NYSE: NVO, best known for Ozempic and Wegovy.
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Global pharmaceutical giant Eli Lilly & Co. NYSE: LLY has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound. Mounjaro is prescribed for Type 2 diabetes but is often used off-label for weight loss.
Hims & Hers shares plunge 12% amid allegations of GLP-1 drug sourcing from ‘shady supplier'
Roughly a month after announcing that it would offer GLP-1 injectable weight-loss drugs comparable to the popular drugs Ozempic and Mounjaro, Hims & Hers Health shares are taking a beating after a new report criticized those offerings, saying that they're being acquired through a “shady supplier.”
Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition
Amylyx Pharmaceuticals, Inc.'s relyvrio for ALS was voluntarily delisted in the U.S. and Canada, but has a chance to target this indication with the advancement of AMX0114; IND filing and trial initiation expected in 2024. Full data from the phase 2 HELIOS trial, using AMX0035 to treat patients with Wolfram syndrome, is expected Fall of 2024. Interim analysis from phase 3 ORION study, using AMX0035 to treat patients with progressive supranuclear palsy, expected mid-2025.
Zealand Pharma shares surge after positive results of weight-loss drug that could contend with GLP-1s
Shares of Zealand Pharma soared on Friday after the Danish biotech company reported positive results from a trial of its experimental weight-loss injection, that could compete with popular GLP-1s drugs.
